INK4a in cell cycle control and carcinogenesis. Mutations, deletions and changes in methylation patterns of p16
Introduction
Although the molecular processes involved in the development and progression of human breast cancer have not been established, it is hypothesized that carcinogenesis results from an accumulation of genetic alterations which provide a clonal growth advantage. This hypothesis has been most rigorously tested in human colon cancers (Fearon and Vogelstein, 1990) ; in breast cancer, the series of events remains unclear.
A class of cyclin-dependent kinase (CDK) inhibitory proteins has been described (Peter and Herskowitz, 1994) . One of these inhibitors, p16
INK4a (also known as CDKN2 or MTS1), speci®cally inhibits activity of the CDK4-cyclin D complex, a key regulator of the progression of eukaryotic cells through the G1 phase of the cell cycle (Serrano et al., 1993) . p16
INK4a maps to chromosome 9p21, a region frequently altered in many tumor types (Olopade et al., 1991) . Much excitement was generated when studies found that the p16 INK4a gene was homozygously deleted at high frequency in cell lines derived from a wide variety of tumor types, suggesting that p16
INK4a may be a tumor suppressor gene which plays a central role in the development of several human cancers (Kamb et al., 1994; Nobori et al., 1994) .
However, subsequent work demonstrated that the overall incidence of mutations or deletions in primary tumors is much lower than that reported for cell lines (Cairns et al., 1994; Spruck III et al., 1994) . In breast carcinoma in particular, although homozygous deletion of p16
INK4a is seen in 40 ± 60% of cell lines (Kamb et al., 1994; Xu et al., 1994) , neither homozygous deletions nor point mutations have been frequently observed in primary breast carcinomas (Xu et al., 1994) .
Nonetheless, it is possible that p16 INK4a is inactivated via an alternative mechanism: DNA methylation (Mohandas et al., 1981) . Approximately one half of all genes have been estimated to have CpG islands within or near their promoters (Antequera and Bird, 1993 ) and methylation of a normally unmethylated 5' CpG island can result in loss of gene expression (Herman et al., 1994) . Since the exon 1 and exon 2 coding sequences of the p16
INK4a gene constitute CpG islands, it has been hypothesized that abnormal DNA methylation may be an alternative mechanism of inactivation of the p16 INK4a gene in primary tumors . Supporting evidence includes the detection of p16
INK4a hypermethylation in primary tumors and the absence of p16
INK4a mRNA expression in methylated cell lines Merlo et al., 1995) . In the only report of p16 INK4a methylation in primary breast carcionoma, 31% (5/16) were found to be methylated . Those authors concluded that hypermethylation of p16
INK4a is a frequent mode of inactivation in breast cancer (as well as other common human cancers). However, there have been no reported evaluations of p16
INK4a methylation in normal breast tissue.
The present study demonstrates that breast carcinoma exhibits DNA hypomethylation and increased mRNA expression of p16
INK4a relative to normal breast tissue. These data suggest that the silencing of p16 INK4a transcription via CpG island hypermethylation is not a key mechanism in the development of breast carcinoma, but rather that the gene is functioning and expressed in breast carcinoma more frequently than in normal breast tissue. These data raise the possibility that the role of p16
INK4a in tumorigenesis is organ speci®c, and suggest that its role is much more complex than has been previously hypothesized.
Results
The methylation status within exon 1 of the p16
INK4a
gene was assessed by Southern blot analysis (Figure 1) . When EagI or SacII sites are unmethylated, a 3.3 kb fragment is detected, indicating that the gene has been cleaved at the restriction site Merlo et al., 1995) . Methylation of EagI or SacII sites is represented by the absence of the 3.3 kb fragment. A 4.3 kb fragment is present in all lanes and may represent hybridization with exon 2 (Hebert et al., 1994) , or a methylated exon 1 (Herman et al., 1994) . A 6.0 kb band is visible after EcoRI digestion alone, as well as after digestion with both EcoRI/EagI and EcoRI/SacII. This 6.0 kb fragment was not only seen in all tissue samples, but also the positive control breast cancer cell lines (T47-D and MDA-MB-468). However, the band was absent in the cell line MCF-7, which has a homozygous deletion of p16
INK4a (Xu et al., 1994) but a wild type p15 gene (Zariwala et al., 1996) . Therefore this fragment may represent the 3' remainder of the p16
INK4a gene, although it has also been suggested to represent cross-hybridization with the p15 gene (Arap et al., 1995) .
A summary of the results of digestion with EcoRI/ EagI and EcoRI/SacII is shown in Table 1 . There were two normal and ®ve primary carcinoma samples in which incomplete methylation data were obtained due to tissue availability. The primary carcinomas were found to be methylated at one (partially methylated) or both (fully methylated) sites in 16/33 (48%) cases. Only 4/33 (12%) of primary carcinomas were fully methylated, whereas 17/33 (52%) were non-methylated. None of the ®ve metastatic carcinomas were fully methylated, whereas 3/5 (60%) were partially methylated and 2/5 (40%) were non-methylated. Surprisingly, all (11/11) normal breast tissue samples were methylated at one or both sites. There was a statistically signi®cant dierence in methylation status between the three types of tissue (Chi square, P50.002). In accordance with previous ®ndings , T47-D exhibited complete methylation, while MDA-MB-468 was unmethylated (data not shown).
Further examination of pairs of normal tissue and primary carcinoma, or primary and metastatic carcinoma from a given individual revealed that within any individual, there was generally a loss of methylation from normal to primary to metastasis ( Figure 2 , Table 2 ). In no case was there an increase in methylation. In the three cases in which both the primary carcinoma and the metastasis demonstrated partial methylation, there was preservation of methylation site speci®city (EagI in all three cases).
RT ± PCR (reverse transcription-polymerase chain reaction) was performed to con®rm loss of transcription in the presence of p16
INK4a methylation (Figure 3 ). Exons 3 and 4 of p53 were ampli®ed to serve as a control for RNA integrity, and were demonstrated in all samples. All non-methylated samples analysed and MDA-MB-468 (non-methylated cell line) demonstrated p16
INK4a mRNA expression (Table 3) . Neither T47-D (methylated cell line) nor any of the methylated samples had detectable p16
INK4a mRNA. Half (3/6) of the partially methylated tissue samples expressed (lanes 3, 5, 7, 11, 17, 19, 21) indicating the exon 1 restriction site was non-methylated. In normal breast tissue (lanes 2, 4, 6, 8, 10, 12, 14, 16, 18, 20) and some primary breast carcinomas (lanes 9, 13, 15) no 3.3 kb band was identi®ed, indicating methylation of the restriction site. A 6.0 kb fragment was detected in all samples. (b) p16
INK4a methylation in normal breast, primary carcinoma, and metastatic carcinoma from an individual patient. Results of EcoRI/SacII digestion of normal breast (lane 1), primary carcinoma (lane 2), and metastatic carcinoma (lane 3) demonstrates exon 1 methylation in the normal tissue, but its absence in the carcinoma specimens (Table 3) .
Discussion
This study is the ®rst to examine primary breast carcinoma, with corresponding metastatic disease and normal breast tissue, for p16
INK4a methylation and expression. The primary breast carcinomas examined had been previously screened by PCR/SSCP, and no p16
INK4a mutations or deletions were found (Rush et al., 1995) . These same results were con®rmed by Southern blotting analysis (data not shown). These ®ndings agree with those of Xu et al., who, using similar methods, found that none of 37 primary breast carcinomas had p16
INK4a mutations (Xu et al., 1994 ). However, it is possible that mutations and deletions might be masked by DNA from other cells in the heterogeneous tumor population or by contaminating normal tissue. This concern was addressed by examining microdissected invasive breast carcinoma and normal breast tissue (Calvano et al., 1997) . Again, no p16
INK4a mutations or deletions were found, suggesting that p16
INK4a must be inactivated via some other mechanism.
In the present study, the hypothesis that hypermethylation of the 5' CpG island of p16
INK4a
represents an important mechanism of gene inactivation in breast carcinoma was addressed. It has been postulated that hypermethylation of DNA leads to the causative alteration in tumorigenesis that involves inactivating tumor suppressor genes and marking chromosome regions for deletion . It may be that the role of methylation in regulation of gene expression is quite complex, with the speci®c gene and tissue determining the requirement for hypomethylation or hypermethylation. For example, for expression of Igf2r to occur, both hypomethylation of the 5'¯anking region and methylation of a speci®c CpG site in an intron are required (StoÈ ger et al., 1993) .
We found that 48% of primary breast carcinomas are at least partially methylated at p16
, not unlike the ®ndings of others . Similarly, 3/5 metastatic carcinomas demonstrated partial methylation. However, it was striking to ®nd that this region was at least partially methylated in all of the normal breast tissue. If the data is further dissected to distinguish partial from full methylation, the differences become even more clear. There is a distinct trend toward hypomethylation as one moves from normal to primary to metastatic carcinoma (see Table 1 ). To further clarify the ®ndings, normal and primary carcinoma, or primary and metastatic carcinoma pairs, from each individual were examined and a progressive loss of methylation from normal to primary and primary to metastatic carcinoma was found.
To verify that p16 INK4a methylation in our samples was associated with the absence of p16
INK4a expression, RT ± PCR was performed on a subset of these samples. This con®rmed the complete absence of p16 lez-Zulueta et al., 1995; Herman et al., 1995; .
Expression of p16 INK4a mRNA was not detected in any of the normal breast samples. In contrast, p16
INK4a mRNA was present in about half of primary tumors and in every metastatic carcinoma examined. The latter ®ndings are similar to those of Brenner et al. (1996) who found normal levels of p16
INK4a mRNA in 10/23 primary breast carcinomas. While Herman et al. did not evaluate p16
INK4a expression in primary breast tumors, they did ®nd that 5/16 breast cancers had hypermethylation of p16
. Since that group has shown a strong correlation between p16
INK4a hypermethylation and expression in cell lines Merlo et al., 1995) , they concluded that the p16 gene is silenced in a large proportion of carcinomas. However, given our results in normal breast tissue, dierent conclusions can be drawn. We have demonstrated that relative to normal breast tissue, carcinoma samples are hypomethylated and more likely to express p16
. Our ®ndings call into question the hypothesis that the loss of functional p16
INK4a plays a key role in breast carcinogenesis, but rather show that the gene is functioning and expressed in breast carcinoma more frequently than in normal breast tissue.
Others have published data in other tumor types that support our ®ndings. DNA from both benign colonic polyps and malignant colon carcinomas have been shown to be substantially hypomethylated as compared to DNA from adjacent normal tissue (Goelz et al., 1985) . In another report, p16
INK4a mRNA was not detected in any of 10 normal brain samples examined (Costello et al., 1996) . GonzalezZulueta et al. (1995) found that only 1/10 (10%) of colon carcinomas showed methylation of the 5' CpG island of p16
INK4a , whereas as 6/10 (60%) corresponding normal samples were extensively methylated. Furthermore, in all (4/4) patients without colon cancer, normal colonic mucosa has p16
INK4a methylation that was accompanied by the absence of p16 INK4a mRNA expression.
Considerable controversy has existed about the role of p16
INK4a in human cancer. Unlike the typical tumor suppressor gene, inactivation does not frequently involve point mutations of one allele and loss of the other. Instead, the two most common mechanisms for loss of p16
INK4a function are homozygous deletion and loss of transcription associated with hypermethylation of 5' CpG regions.
Our data support the hypothesis that methylation of the CpG island within exon 1 of p16
INK4a silences gene expression. In addition, the proportion for primary carcinomas exhibiting p16
INK4a methylation is similar to that reported previously. However, in order to better understand the functional signi®cance of DNA methylation in a cancer cell, they must be viewed in relation to that seen in normal tissue (Baylin, 1992) . This study has demonstrated that normal breast tissue exhibits p16 INK4a methylation even more frequently than breast carcinoma. p16
INK4a expression in carcinoma cells may represent an unsuccessful attempt to limit growth in cells lacking some other normal mechanisms of control. In breast and other cell types, further studies are needed to better de®ne the extent and character of involvement of p16
INK4a in carcinogenesis.
Materials and methods

Tissue samples
Tissue samples (13 normal breast, 38 primary carcinomas, and 5 metastatic carcinomas) were collected from 38 patients with histologically proven carcinoma of the breast. Genomic DNA was extracted from frozen tissue using phenol/chloroform followed by ethanol precipitation. All primary tumor and normal breast tissue samples were previously determined to have no mutations or deletions by PCR/SSCP (polymerase chain reaction/single-strand conformation polymorphism) analysis (Rush et al., 1995) .
Control cell lines
MCF-7, T47-D and MDA-MB-468 cell lines were used as controls. All cell lines were obtained from American Type Culture Collection (Rockville, MD) and were grown in either RPMI 1640 supplemented with 5 ± 10% fetal bovine serum or DME HG: F12 with 10% fetal bovine serum depending on the growth requirements of each cell line. Genomic DNA was extracted from the above cell lines using phenol/chloroform followed by ethanol precipitation.
INK4a methylation was assessed in all samples of normal breast, primary and metastatic carcinoma, as well as the three cell lines. Each sample was assessed at least twice in the following manner. Seven to 10 mg DNA was digested with EcoRI (10 units/mg) alone and in combination with the methylation-sensitive enzymes EagI or SacII (15 units/ mg) as speci®ed by the manufacturer (New England Biolabs, Beverly, MA). EcoRI provides a¯anking cut for p16
INK4a as well as a cleavage site between exons 1 and 2; EagI and SacII have restriction sites in exon 1 but not exons 2 or 3. To increase the completeness of digestion, DNA was cleaved with an excess of restriction endonucleases. Digestions were electrophoresed on a 1.0% agarose gel at 17V for 18 h and transferred to Hybond N + nylon membranes (Amersham, Arlington Heights, IL). The blots were hybridized to a randomly primed 32 P-p16 INK4a cDNA (Ramdom primed DNA labeling kit, Stratagene, La Jolla, CA). The plasmid bluescript (pSK) (Stratagene) containing the p16
INK4a cDNA, originated from Dr David Beach (Cold Spring Harbor Laboratory, Cold Sping Harbor, NY), and was kindly provided by Dr Mark Moasser (Rockefeller Research Laboratories, Memorial Sloan-Kettering Cancer Center). The blots were hybridized in a solution containing 50% formamide, 56SSPE, 0.1% SDS, 56Denhardts, and 0.1 mg/ml sonicated salmon sperm DNA at 42 ± 438C overnight. After hybridization, the membranes were washed at a ®nal stringency with a solution of 0.16SSPE/0.1% SDS and subjected to autoradiography using Biomax MS ®lm (Eastman, Kodak, Rochester, NY) for 2 ± 5 days with an intensifying screen.
p16
INK4a expression
Total RNA was extracted from the cell lines MCF-7, T47-D, MDA-MB-468 and a subset of frozen tissue samples (6 normal, 11 primary, and 4 metastatic carcinomas) using TRIzol Reagent (Gibco-BRL, Gaithersburg, MD). Total RNA (6 mg) was reverse-transcribed with and without Superscript II RNAse H-(Gibco-BRL) reverse transcriptase (200 units) in the presence of random hexamers (250 ng) and dNTPs (10 mM). p16 INK4a was ampli®ed using a sense primer located in exon 1 and an antisense primer located in exon 2 . To control for RNA integrity, a p53 fragment spanning exons 3 and 4 was also ampli®ed for all samples. The cDNA's were ampli®ed as described previously (Gonzalez-Zulueta et al., 1995; Merlo et al., 1995) . All PCR products were resolved on 2% agarose gels and visualized by ethidium bromide. The p16
INK4a sense primer was (5'-AGC CTT CGG CTG ACT GGC TGG-3') and the antisense primer was (5'-CTG CCC ATC ATC ATG ACC TGG A-3'). The p53 sense primer was (5'-TCC CAG AAT GCC AGA GGC-3') and the antisense primer was (5'-AGT ACA ACG ACA CTG ACG AAC-3').
